Table of Content

Open Access iconOpen Access

ARTICLE

Canadian guidelines for the management of benign prostatic hyperplasia

J. Curtis Nickel1, Sender Herschorn2, Jacques Corcos2, Bryan Donnelly1, Doug Drover2, Mostafa Elhilali1, Larry Goldenberg1, John Grantmyre2, Bruno Laroche2, Richard Norman1, Bruce Piercy1, Karen Psooy2, Gary Steinhoff1, John Trachtenberg1, Fred Saad1, Simon Tanguay1

1 Canadian Prostate Health Council
2 Canadian Urological Association Guidelines Committee
Address correspondence to Dr. J. Curtis Nickel, Department of Urology, Queen’s University, Kingston General Hospital, Kingston, Ontario K7L 2V7 Canada

Canadian Journal of Urology 2005, 12(3), 2677-2683.

Abstract

Objective: To develop the first Canadian guidelines for the management of lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH).
Methods: These guidelines, developed under a mandate provided by the Canadian Urological Association (CUA), were a collaborative effort between the CUA guidelines committee and the Canadian Prostate Health Council. BPH guidelines developed by the American Urological Association, the European Association of Urology, the World Health Organization International Consultation on BPH, and similar committees from Germany, Sweden and Australia were reviewed. The committee further reviewed a systematic literature search, updated to May 2004, and systematically derived Canadian urological opinion data.
Results: The subsequent Canadian BPH guidelines were developed as an evidence based consensus among the committee members. Mandatory evaluation includes history, physical examination and urinalysis, while a symptom inventory and PSA in selected patients are recommended. Serum creatinine, uroflow, voiding diary, post void residual and sexual function questionnaire are optional. Unless there is an indication, other related tests are not recommended. Treatment choices should be governed by the severity of the symptoms, bother and patient preference. Guidelines for medical, surgical and minimally invasive treatment as well as special considerations are described in terms of guideline, option and recommendation.
Conclusions: Diagnostic and treatment guidelines for BPH reflect the Canadian social priorities, economics, socialized medical practice, manpower issues, and medicolegal considerations.

Keywords

benign prostatic hyperplasia, BPH, lower urinary tract symptoms, LUTS, diagnosis, treatment, guideline

Cite This Article

APA Style
Nickel, J.C., Herschorn, S., Corcos, J., Donnelly, B., Drover, D. et al. (2005). Canadian guidelines for the management of benign prostatic hyperplasia. Canadian Journal of Urology, 12(3), 2677–2683.
Vancouver Style
Nickel JC, Herschorn S, Corcos J, Donnelly B, Drover D, Elhilali M, et al. Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urology. 2005;12(3):2677–2683.
IEEE Style
J.C. Nickel et al., “Canadian guidelines for the management of benign prostatic hyperplasia,” Can. J. Urology, vol. 12, no. 3, pp. 2677–2683, 2005.



cc Copyright © 2005 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 37

    View

  • 31

    Download

  • 0

    Like

Share Link